Richter Transformation
8
4
4
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
12.5%
1 terminated out of 8 trials
0.0%
-86.6% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (8)
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation
Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
DALY II USA/ MB-CART2019.1 for DLBCL
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
A Study of NX-1607 in Adults With Advanced Malignancies
R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL